A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
Clinical trial NCT07536308 · RECRUITING
Trial details
- NCT number
- NCT07536308
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-26
- Primary completion
- 2027-04-29
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.